LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 187

Search options

  1. Article ; Online: Feasibility and Validity of In-Home Self-Collected Capillary Blood Spot Screening for Type 1 Diabetes Risk.

    Sing, Anna B E / Naselli, Gaetano / Huang, Dexing / Watson, Kelly / Colman, Peter G / Harrison, Leonard C / Wentworth, John M

    Diabetes technology & therapeutics

    2024  Volume 26, Issue 2, Page(s) 87–94

    Abstract: Aims: ...

    Abstract Aims:
    MeSH term(s) Humans ; Diabetes Mellitus, Type 1 ; Feasibility Studies ; Mass Screening ; Autoantibodies ; Sensitivity and Specificity
    Chemical Substances Autoantibodies
    Language English
    Publishing date 2024-01-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1452816-2
    ISSN 1557-8593 ; 1520-9156
    ISSN (online) 1557-8593
    ISSN 1520-9156
    DOI 10.1089/dia.2023.0345
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5269: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial.

    Wentworth, John M / Colman, Peter G

    Diabetes, obesity & metabolism

    2020  Volume 22, Issue 7, Page(s) 1215–1219

    Abstract: The methionine aminopeptidase 2 (MetAP2) inhibitor ZGN-1061 lowered weight and improved glucose in preclinical studies. We sought to determine its efficacy and safety by performing a multicentre, phase 2, randomized controlled trial involving overweight ... ...

    Abstract The methionine aminopeptidase 2 (MetAP2) inhibitor ZGN-1061 lowered weight and improved glucose in preclinical studies. We sought to determine its efficacy and safety by performing a multicentre, phase 2, randomized controlled trial involving overweight and obese adults with type 2 diabetes and HbA1c between 7% and 11% inclusive. Participants were randomized to receive subcutaneous treatment with placebo or 0.05, 0.3, 0.9 or 1.8 mg ZGN-1061 every third day for 12 weeks. The primary outcome was change in HbA1c at week 12. Relative to placebo, the 0.9 and 1.8 mg doses induced clinically meaningful reductions in HbA1c of 0.6% (95% CI 0.2% to 0.9%; P = 0.0006) and 1.0% (95% CI 0.6% to 1.4%; P < 0.0001), respectively. The 1.8 mg dose also induced weight loss of 2.2% (95% CI 1.1% to 3.3%; P = 0.0002). The incidence of adverse events was balanced across the treatment groups. We conclude that MetAP2 inhibition with ZGN-1061 for 12 weeks improved glucose control and aided weight loss in overweight and obese people with type 2 diabetes. However, given safety issues, Zafgen has discontinued MetAP2 inhibitor development.
    MeSH term(s) Adult ; Aminopeptidases ; Azetidines ; Blood Glucose ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Double-Blind Method ; Humans ; Hypoglycemic Agents/therapeutic use ; Metalloendopeptidases ; Morpholines ; Obesity/complications ; Obesity/drug therapy ; Overweight/complications ; Overweight/drug therapy
    Chemical Substances Azetidines ; Blood Glucose ; Hypoglycemic Agents ; Morpholines ; ZGN-1061 ; Aminopeptidases (EC 3.4.11.-) ; methionine aminopeptidase 2 (EC 3.4.11.18) ; Metalloendopeptidases (EC 3.4.24.-)
    Language English
    Publishing date 2020-03-03
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.14009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5442: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Glycaemic trajectory and predictors of suboptimal glycaemic control in people with type 2 diabetes.

    Pathiraja, Nipuni P / Colman, Peter G / Wentworth, John M

    Internal medicine journal

    2021  Volume 50, Issue 11, Page(s) 1415–1418

    Abstract: We aimed to describe the glycaemic trajectory and define characteristics associated with suboptimal glycaemic control in the type 2 diabetes clinic. Higher glycosylated haemoglobin (HbA1c) at 1 year was associated with higher baseline HbA1c, concurrent ... ...

    Abstract We aimed to describe the glycaemic trajectory and define characteristics associated with suboptimal glycaemic control in the type 2 diabetes clinic. Higher glycosylated haemoglobin (HbA1c) at 1 year was associated with higher baseline HbA1c, concurrent anti-depressant or antipsychotic medication, higher bodyweight and low treatment adherence. These characteristics may help identify patients unlikely to attain HbA1c treatment targets and be better served by a different model of care.
    MeSH term(s) Blood Glucose ; Body Weight ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Glycated Hemoglobin A/analysis ; Glycemic Control ; Humans ; Hypoglycemic Agents
    Chemical Substances Blood Glucose ; Glycated Hemoglobin A ; Hypoglycemic Agents
    Language English
    Publishing date 2021-01-20
    Publishing country Australia
    Document type Journal Article
    ZDB-ID 2045436-3
    ISSN 1445-5994 ; 1444-0903
    ISSN (online) 1445-5994
    ISSN 1444-0903
    DOI 10.1111/imj.15059
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 792: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 424: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Continuous glucose monitoring has an increasing role in pre-symptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing.

    Joshi, Kriti / Harris, Mark / Cotterill, Andrew / Wentworth, John M / Couper, Jennifer J / Haynes, Aveni / Davis, Elizabeth A / Lomax, Kate E / Huynh, Tony

    Clinical chemistry and laboratory medicine

    2023  Volume 62, Issue 1, Page(s) 41–49

    Abstract: Type 1 diabetes (T1D) is well-recognised as a continuum heralded by the development of islet autoantibodies, progression to islet autoimmunity causing beta cell destruction, culminating in insulin deficiency and clinical disease. Abnormalities of glucose ...

    Abstract Type 1 diabetes (T1D) is well-recognised as a continuum heralded by the development of islet autoantibodies, progression to islet autoimmunity causing beta cell destruction, culminating in insulin deficiency and clinical disease. Abnormalities of glucose homeostasis are known to exist well before the onset of typical symptoms. Laboratory-based tests such as the oral glucose tolerance test (OGTT) and glycated haemoglobin (HbA
    MeSH term(s) Child ; Humans ; Diabetes Mellitus, Type 1/diagnosis ; Blood Glucose ; Blood Glucose Self-Monitoring ; Glucose Tolerance Test ; Glycated Hemoglobin ; Autoantibodies
    Chemical Substances Blood Glucose ; Glycated Hemoglobin ; Autoantibodies
    Language English
    Publishing date 2023-06-23
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1418007-8
    ISSN 1437-4331 ; 1434-6621 ; 1437-8523
    ISSN (online) 1437-4331
    ISSN 1434-6621 ; 1437-8523
    DOI 10.1515/cclm-2023-0234
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 121: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: In-field detection and characterization of B/Victoria lineage deletion variant viruses causing early influenza activity and an outbreak in Louisiana, 2019.

    Shu, Bo / Wilson, Malania M / Keller, Matthew W / Tran, Ha / Sokol, Theresa / Lee, Grace / Rambo-Martin, Benjamin L / Kirby, Marie K / Hassell, Norman / Haydel, Danielle / Hand, Julie / Wentworth, David E / Barnes, John R

    Influenza and other respiratory viruses

    2024  Volume 18, Issue 1, Page(s) e13246

    Abstract: Background: In 2019, the Louisiana Department of Health reported an early influenza B/Victoria (B/VIC) virus outbreak.: Method: As it was an atypically large outbreak, we deployed to Louisiana to investigate it using genomics and a triplex real-time ... ...

    Abstract Background: In 2019, the Louisiana Department of Health reported an early influenza B/Victoria (B/VIC) virus outbreak.
    Method: As it was an atypically large outbreak, we deployed to Louisiana to investigate it using genomics and a triplex real-time RT-PCR assay to detect three antigenically distinct B/VIC lineage variant viruses.
    Results: The investigation indicated that B/VIC V1A.3 subclade, containing a three amino acid deletion in the hemagglutinin and known to be antigenically distinct to the B/Colorado/06/2017 vaccine virus, was the most prevalent circulating virus within the specimens evaluated (86/88 in real-time RT-PCR).
    Conclusion: This work underscores the value of portable platforms for rapid, onsite pathogen characterization.
    MeSH term(s) Humans ; Influenza, Human/epidemiology ; Influenza Vaccines ; Disease Outbreaks ; Louisiana/epidemiology
    Chemical Substances Influenza Vaccines ; L 644711 (SC0Y88002K)
    Language English
    Publishing date 2024-01-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 2274538-5
    ISSN 1750-2659 ; 1750-2640
    ISSN (online) 1750-2659
    ISSN 1750-2640
    DOI 10.1111/irv.13246
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6568: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Long-term impact of weight loss for people with overweight but not obesity, and with type 2 diabetes: 10-year outcomes of a randomized trial of gastric band surgery.

    Qi, Qi Yang Damien / Playfair, Julie / Brown, Wendy A / Burton, Paul / O'Brien, Paul E / Wentworth, John M

    Diabetes, obesity & metabolism

    2023  Volume 25, Issue 6, Page(s) 1464–1472

    Abstract: Aim: Randomized trials reporting 5-year outcomes have shown bariatric surgery  to induce diabetes remission and improve cardiovascular risk. However, the longer-term effects of surgery are uncertain, with only one randomized trial reporting 10-year ... ...

    Abstract Aim: Randomized trials reporting 5-year outcomes have shown bariatric surgery  to induce diabetes remission and improve cardiovascular risk. However, the longer-term effects of surgery are uncertain, with only one randomized trial reporting 10-year diabetes outcomes in people with obesity. We aimed to compare 10-year diabetes outcomes of people who are overweight but not obese, randomly assigned to receive either multidisciplinary diabetes care, or multidisciplinary diabetes care combined with gastric band (GB) surgery.
    Methods: Between 2009 and 2011, 51 adults were randomized. After 5 years, they were discharged to receive community care and reassessed after 10 years. The primary outcome was diabetes remission, defined as glycated haemoglobin (HbA1c) <6.5% (48 mmol/mol) without glucose-lowering medication.
    Results: Forty-one participants (20 medical and 21 GB) completed the 10-year assessment. The median (Q1, Q3) weight loss in the GB group was 9.8 (6.7, 16.3)% at 10 years compared with 5.6 (3.4, 7.6)% in the medical group (median difference 4.2%; p = .008). Diabetes remission occurred in five GB participants and no medical participants (relative risk 0.76, 95% CI: 0.55-0.93, p = .048). GB participants used fewer glucose-lowering medications at 10 years but HbA1c, fasting glucose, calculated cardiovascular risk, quality-of-life and incident diabetes complications did not differ significantly between the groups.
    Conclusion: When compared with medical care, GB surgery achieved greater weight loss and modestly increased the likelihood of diabetes remission. However, it did not improve HbA1c, cardiovascular risk or quality of life.
    MeSH term(s) Adult ; Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/therapy ; Overweight/complications ; Overweight/therapy ; Glycated Hemoglobin ; Quality of Life ; Treatment Outcome ; Obesity/complications ; Obesity/epidemiology ; Obesity/surgery ; Bariatric Surgery ; Glucose ; Weight Loss
    Chemical Substances Glycated Hemoglobin ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2023-02-14
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.14992
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5442: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetes.

    Wentworth, John M / Fourlanos, Spiros / Colman, Peter G / Harrison, Leonard C

    Metabolism open

    2020  Volume 5, Page(s) 100021

    Abstract: Introduction: Sodium-glucose linked transporter (SGLT) inhibitors could improve glycaemia and simplify insulin regimens in recent-onset type 1 diabetes (T1D), provided they were well-tolerated and safe. This study aimed to determine the feasibility and ... ...

    Abstract Introduction: Sodium-glucose linked transporter (SGLT) inhibitors could improve glycaemia and simplify insulin regimens in recent-onset type 1 diabetes (T1D), provided they were well-tolerated and safe. This study aimed to determine the feasibility and safety of a SGLT inhibitor for the treatment of recent-onset T1D.
    Method: An open label, prospective pilot study in adults with recent-onset T1D was performed. Empagliflozin, 25 mg orally daily, was given in combination with insulin and multidisciplinary care during a 24-week treatment phase, followed by wash-out visits at weeks 30 and 36.
    Results: Fourteen participants (4 women; median age 26 years) began and 13 completed the study. No treatment-emergent serious adverse events were observed, with fatigue and genital infection the most common side-effects. Four participants stopped mealtime insulin for at least one month when taking empagliflozin. At week 24, median weight, HbA1c and insulin dose decreased by 4.4 kg, 1.5% (17 mmol/mol) and 0.03 units/kg/day, respectively. Meal-stimulated C-peptide was maintained during the treatment phase and then decreased at 36 weeks.
    Conclusions: Treatment of adults with empagliflozin within 100 days of T1D diagnosis appeared safe and was associated with improved clinical outcomes. These findings justify a definitive trial to determine if SGLT inhibitors simplify treatment regimens and improve clinical outcomes in recent-onset T1D.
    Registration: ACTRN12617000016336.
    Language English
    Publishing date 2020-01-03
    Publishing country England
    Document type Journal Article
    ISSN 2589-9368
    ISSN (online) 2589-9368
    DOI 10.1016/j.metop.2020.100021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Correction to: Validation in the general population of a C-peptide estimate equation to measure beta cell function in recent-onset type 1 diabetes.

    Wang, Joanna / Bediaga, Naiara / Mallone, Roberto / Larger, Etienne / Harrison, Leonard C / Wentworth, John M

    Acta diabetologica

    2020  Volume 58, Issue 1, Page(s) 119

    Language English
    Publishing date 2020-10-16
    Publishing country Germany
    Document type Published Erratum
    ZDB-ID 1097676-0
    ISSN 1432-5233 ; 0940-5429
    ISSN (online) 1432-5233
    ISSN 0940-5429
    DOI 10.1007/s00592-020-01616-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 611: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Validation in the general population of a C-peptide estimate equation to measure beta cell function in recent-onset type 1 diabetes.

    Wang, Joanna / Bediaga, Naiara / Mallone, Roberto / Larger, Etienne / Harrison, Leonard C / Wentworth, John M

    Acta diabetologica

    2020  Volume 58, Issue 1, Page(s) 115–117

    Language English
    Publishing date 2020-09-17
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1097676-0
    ISSN 1432-5233 ; 0940-5429
    ISSN (online) 1432-5233
    ISSN 0940-5429
    DOI 10.1007/s00592-020-01604-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 611: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Iron Overload Combined with Islet Autoimmunity Causes ‘Ferro-immune’ Hybrid Diabetes

    Joanna Y Gong / John M Wentworth / Christopher J Yates / Qi Yang Damien Qi / Spiros Fourlanos

    Journal of Clinical and Diagnostic Research, Vol 17, Iss 12, Pp 01-

    A Case Series

    2023  Volume 03

    Abstract: Iron’s role in diabetes pathophysiology is underrecognised. Authors describe three cases (two females and one male) with evidence of ‘ferro-immune’ hybrid diabetes, HFE C282Y homozygosity with islet autoimmunity. Case one describes iron overload followed ...

    Abstract Iron’s role in diabetes pathophysiology is underrecognised. Authors describe three cases (two females and one male) with evidence of ‘ferro-immune’ hybrid diabetes, HFE C282Y homozygosity with islet autoimmunity. Case one describes iron overload followed by classical autoimmune diabetes. A 20-year-old female presented with non transfusion-dependent hereditary spherocytosis, contributing to hepatic iron overload. At the age of 26 years, the patient presented with diabetic ketoacidosis and elevated Glutamic Acid Decarboxylase (GAD) (50.5 U/mL) and Islet Antigen 2 (IA-2) (>4,000 U/mL) autoantibodies, and commenced insulin therapy. Two months after her diabetes diagnosis, she began iron chelation therapy. Case two describes haemochromatosis followed by adultonset diabetes. A fit 78-year-old woman was diagnosed with haemochromatosis at the age of 58 years and presumed to have Type 2 Diabetes (T2D) at the age of 66 years. However, subsequent testing revealed GAD autoantibody positivity (24 U/mL) with normal C-peptide levels (0.55 nmol/L). Her diabetes was diet-controlled, and her transferrin saturation normalised while GAD seropositivity resolved spontaneously. Case three describes slowly-progressive autoimmune diabetes preceding haemochromatosis. A lean man was diagnosed with latent autoimmune diabetes in adulthood with elevated GAD autoantibodies (11 U/mL). At the age of 81 years, he was diagnosed with haemochromatosis (transferrin saturation 61%), which was followed by a decline in glycaemic control (HbA1c 8.3% to 9.0%). A paired fasting glucose (10.8 mmol/L) and C-peptide (0.15 nmol/L) indicated insulin deficiency, and he remains dependent on insulin therapy. Reducing iron levels through venesection or iron chelation may help decrease islet inflammation and potentially, autoimmunity. A family history of haemochromatosis or an atypical diabetes presentation should prompt an investigation into iron status. Additionally, a low C-peptide level in the presence of haemochromatosis should prompt an investigation into ...
    Keywords autoimmune ; chelation ; genetic ; haemochromatosis ; insulin deficiency ; Medicine ; R
    Subject code 571
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher JCDR Research and Publications Private Limited
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top